AVI BioPharma Discontinues Hep C Candidate Due To Insufficient Potency
This article was originally published in The Pink Sheet Daily
Executive Summary
Company to refocus development of its Neugene antisense compounds on cardiovascular and genetic diseases.
You may also be interested in...
Takeda, Santhera Extend Partnership On Idebenone To Duchenne Muscular Dystrophy
Takeda and the Swiss specialty pharma Santhera Pharmaceuticals are extending an existing collaboration on SNT-MC17 (idebenone) for the neuromuscular disease Friedreich's Ataxia to include a second indication for Duchenne muscular dystrophy, the firms announced Aug. 2
Idenix Focusing On HIV Program, Tyzeka Launch Following Clinical Hold On Hep C Candidate
FDA decision stems mainly from GI concerns that have dogged valopicitabine development, Idenix said.
Orphan Drug Czar Will Push Legislators For More Grant Funding In 2008
For the past 15 years, funding for the grants program at FDA's Office of Orphan Products Development has remained stagnant at $14 million